CASTLEFORD, England, June 27, 2012 /PRNewswire/ --
We are pleased to announce the launch of generic Ibandronic Acid 150mg film-coated tablets.
Ibandronic Acid is a generic version of Bonviva® (Ibandronic Acid) from Roche. It is indicated in the treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1 of SPC for further details).
Ibandronic Acid is available immediately in the award-winning Teva 360 livery as follows:
Strength and pack size 150mg x 1 150mg x 3 Brand Price GBP18.40 GBP55.21 Initial Teva retail price GBP12.88 GBP38.65
Kim Innes, Commercial Director at Teva, said: "We've now launched 21 products this year including ten on day one of patent expiry, in a variety of strengths and pack sizes."
New or existing customers can order through their local Teva Territory Sales Manager, through major wholesalers, or call 0800-085-8621
To find out more about Teva UK Limited, visit http://www.tevauk.com.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.
1. A reduction in the risk of vertebral fractures has been demonstrated; efficacy on femoral neck fractures has not been established.
For media enquiries, contact the Teva UK Limited Media team on +44(0)1977-628500, or email email@example.com.
SOURCE Teva UK Limited